The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The inspections concluded with no Form 483 observations or significant critical findings
Subscribe To Our Newsletter & Stay Updated
